Moreover, circZNF215 competitively binds to PRDX1, inhibiting the interaction between PRDX1 and PTEN, thereby reducing the activity of the PTEN/AKT signaling pathway and promoting tumor metastasis as well as ipatasertib resistance.106. Here, PRDX1 is linked to neoplasm.